Additional Positive Data From Pivotal ASPEN Study of Brensocatib in Patients With Bronchiectasis to Be Presented at the 7th World Bronchiectasis Conference
Additional Positive Data From Pivotal ASPEN Study of Brensocatib in Patients With Bronchiectasis to Be Presented at the 7th World Bronchiectasis Conference
—New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Brensocatib 25 mg Versus Placebo—
新的图表描绘了52周的FEV1数据，说明Brensocatib 25 mg相对于安慰剂引起的肺功能下降明显减少。
—Additional Exploratory Endpoints to be Presented, Including FVC and Patient-Reported BEST Score—
还将呈现其他探索性终点，包括FVC和患者报告的BEST评分。
BRIDGEWATER, N.J., July 3, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that additional positive results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis, will be presented tomorrow, July 4, 2024, at the 7th World Bronchiectasis Conference (WBC) in Dundee, Scotland. Slides from this presentation can be found here.
纳斯达克全球生物制药公司Insmed于2024年7月3日表示， ASPEN研究将于2024年7月4日在苏格兰邓迪召开的第7届世界支气管扩张症大会上公布额外的积极结果。该研究是一项全球性的随机、双盲、安慰剂对照的Ⅲ期研究，旨在评估brensocatib对非囊性纤维化支气管扩张症患者的疗效、安全性和耐受性。th此次演示的幻灯片可以在此处找到。